eviegarcia0815. I encourage you to go a little bit into the science and review the side effects of Vpak vs Harvoni. If the prices are similar, I believe Doctors will prescribe Harvoni first and foremost. Consequently ABBV will quickly lose the small amount of market share it currently has. Once price becomes less of an issue, the debate will concentrate on the topics of efficacy and safety, right where it should have been all along. GTLA
Don't buy until after the secondary. Buying because a stock seems cheap is a very bad idea. It'll be cheap for a very good reason, and that's when you need to stay away. Too bad they don't have a button for "I hate this stock, wish I never bought it"
Obviously someone wants a lot more shares. Did JPM just realize someone miscounted? Seriously, is this short squeeze happening to cover the shares they have already "on loan", (as the document says) or is there a deal in the works, and they are calling the shares back for some sort of package deal? This is very weird, shorts won't be called in until the 15th, right? Can someone please shed some light on this?
Traderrook, Thank you for your information and the civility you bring to any board. I remember when message boards were filled with this type of post, now they seem to be filled with everything but. GTLA and happy trading!
cirodrick: In two sentences, you summed up what they should have said in the conference call. A lower cost pill means more lives saved, far more patients treated overall, far less pushback by the insurers and less warehousing by all. concerned.